63630-08-0

Upstream product

• 864529-66-8 N-[4-(2-azidoethyl)phenyl]acetamide 
• 6325-43-5 3-(4-acetamidophenyl)propanoic acid 
• 25025-06-3 N-(4-cyanomethyl-phenyl)-acetamide 

Downstream Products

• 1108732-93-9 N-[2-(4-acetylaminophenyl)ethyl]propionamide 
• 1108732-94-0 N-[4-(2-isopropylaminoethyl)phenyl]acetamide 
• 100-02-7 4-nitro-phenol 
• 94838-59-2 tert-butyl 4-aminophenethylcarbamate 
• 1425051-44-0 C₁₃H₁₅N₃O₂ 
• 637335-01-4 N-(4-{2-[3-butyl-1-(2-fluorobenzyl)-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-ylamino]-ethyl}-phenyl)-acetamide 
• 177945-99-2 1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(4-acetylaminophenyl)ethylamino]piperidine 

Relevant academic research and scientific papers

Amide substituted xanthine derivatives

The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula I and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.